These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38299143)

  • 41. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment management for
    Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
    Haugh AM; Osorio RC; Francois RA; Tawil ME; Tsai KK; Tetzlaff M; Daud A; Vasudevan HN
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma.
    Nebhan CA; Johnson DB
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):137-145. PubMed ID: 31997676
    [No Abstract]   [Full Text] [Related]  

  • 45. [Immune checkpoint inhibitors for treatment of advanced stage melanoma].
    Lupu J; Herrscher H; Robert C
    Rev Prat; 2020 May; 70(5):471-474. PubMed ID: 33058629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
    Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
    Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The therapeutic potential of targeting minimal residual disease in melanoma.
    Patel RP; Somasundram PM; Smith LK; Sheppard KE; McArthur GA
    Clin Transl Med; 2023 Mar; 13(3):e1197. PubMed ID: 36967556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
    Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.
    Serra F; Barruscotti S; Dominioni T; Zuccarini A; Pedrazzoli P; Chiellino S
    Curr Oncol Rep; 2021 May; 23(7):84. PubMed ID: 34009481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
    Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
    Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
    [No Abstract]   [Full Text] [Related]  

  • 51. A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
    Mallardo D; Fordellone M; White A; Vowinckel J; Bailey M; Sparano F; Sorrentino A; Mallardo M; Facchini BA; De Filippi R; Ferrara G; Vanella V; Beeler K; Chiodini P; Cesano A; Warren S; Ascierto PA
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit.
    Ochenduszko S; Puskulluoglu M; Pacholczak-Madej R; Ruiz-Millo O
    Crit Rev Oncol Hematol; 2024 Oct; 202():104443. PubMed ID: 39025250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy.
    Pickering C; Aiyetan P; Xu G; Mitchell A; Rice R; Najjar YG; Markowitz J; Ebert LM; Brown MP; Tapia-Rico G; Frederick D; Cong X; Serie D; Lindpaintner K; Schwarz F; Boland GM
    Front Immunol; 2023; 14():1187332. PubMed ID: 37388743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The proportion of circulating CD45RO
    Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
    Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
    Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
    Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions.
    Shui IM; Scherrer E; Frederickson A; Li JW; Mynzhassarova A; Druyts E; Tawbi H
    Melanoma Res; 2022 Dec; 32(6):393-404. PubMed ID: 36223314
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
    Augustin RC; Luke JJ
    Am J Clin Dermatol; 2024 May; 25(3):421-434. PubMed ID: 38409643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
    Langan EA; Budner K; Zillikens D; Terheyden P
    Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.